Boehringer In­gel­heim inks chron­ic liv­er dis­ease re­search pact with Ochre Bio

Boehringer In­gel­heim is pay­ing Ochre Bio $35 mil­lion in up­front and near-term pay­ments to dis­cov­er new treat­ments for chron­ic liv­er dis­eases like meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis.

Ochre Bio will be re­spon­si­ble for dis­cov­er­ing new tar­gets for treat­ments that could boost the liv­er’s self-re­pair abil­i­ties, ac­cord­ing to Mon­day’s an­nounce­ment. The goal of the part­ner­ship is to de­vel­op ther­a­pies that could slow, or even re­verse, liv­er dam­age in late-stage liv­er dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER